Daniel Lochner
Director of Finance/CFO bei OYSR POIN
Profil
Daniel Lochner is currently the Chief Financial & Business Officer at Oyster Point Pharma, Inc. He previously worked as a Portfolio Manager at Goldman Sachs Asset Management LP from 2005 to 2019.
Mr. Lochner holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from the University of Richmond.
Aktive Positionen von Daniel Lochner
| Unternehmen | Position | Beginn |
|---|---|---|
| OYSR POIN | Director of Finance/CFO | 01.07.2019 |
Ehemalige bekannte Positionen von Daniel Lochner
| Unternehmen | Position | Ende |
|---|---|---|
Goldman Sachs Asset Management LP
 Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Portfolio Manager-Equities | 01.07.2019 |
Ausbildung von Daniel Lochner
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| University of Richmond | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Goldman Sachs Asset Management LP
Goldman Sachs Asset Management LP Investment ManagersFinance Goldman Sachs Asset Management LP (GSAMLP) is a SEC-registered investment advisor headquartered in New York City. The firm is a wholly owned subsidiary of GSAM Holdings LLC, and their ultimate parent is Goldman Sachs Group, Inc. (NYSE: GS). Founded in 1988, GSAMLP provides investment solutions to a range of individual and institutional investors worldwide. | Finance |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. Pharmaceuticals: MajorHealth Technology Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ. | Health Technology |
